Journals / Diagnostic and Interventional Radiology / 2020 / Cilt: 26 - Sayı: 1

The Neuroimaging Features of Rathke's Cleft Cysts in Children with Endocrine-related Diseases

Pages
61–67
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Most RCCs showed neither fluid intensity nor intensity due to high protein content on MRI, and all RCCs had an abnormal signal on T2-weighted imaging, thus eliminating the need to administer a contrast agent at follow-up imaging of the patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:PURPOSE We aimed to evaluate the frequency and neuroimaging features of Rathke's cleft cysts (RCCs) in children examined for endocrine-related diseases and to determine changes in the neuroimaging features of RCCs during the follow-up of children.
📊
Key Findings & Data:METHODS After approval by the local ethics committee, the medical records and contrast-enhanced pituitary MRI of 833 children (boys/girls, 338/495; mean age±SD, 9.4±3.7 years) were retrospectively reviewed between January 2016 and January 2019.
💡
Conclusion & Impact:Most RCCs showed neither fluid intensity nor intensity due to high protein content on MRI, and all RCCs had an abnormal signal on T2-weighted imaging, thus eliminating the need to administer a contrast agent at follow-up imaging of the patients.
🔬Design:Review & Systematic Survey
📍Scope:2016 Verileri
⚙️Variables:Domain Parameters

Özet

PURPOSE We aimed to evaluate the frequency and neuroimaging features of Rathke's cleft cysts (RCCs) in children examined for endocrine-related diseases and to determine changes in the neuroimaging features of RCCs during the follow-up of children. We hypothesize that RCCs are being more commonly diagnosed in children with endocrine-related diseases and most of the RCCs show neither fluid intensity nor intensity due to high protein content on magnetic resonance imaging (MRI). METHODS After approval by the local ethics committee, the medical records and contrast-enhanced pituitary MRI of 833 children (boys/girls, 338/495; mean age±SD, 9.4±3.7 years) were retrospectively reviewed between January 2016 and January 2019. The size, location, signal intensities, and postcontrast enhancement pattern of RCCs were assessed by a pediatric radiologist. Same imaging features were also independently reviewed by another radiologist to determine the interobserver agreement by using the kappa statistics (κ) and intraclass correlation coefficient (ICC). RESULTS RCC was evident on MRI in 13.5% of the patients (boys/girls, 39/74; mean age±SD, 9.8±3.9 years). The mean size of RCCs was 5.5 mm (range, 3.1–8.5 mm). An RCC frequency higher than expected was found in patients with central precocious puberty, diabetes insipidus, and hypersecretion of prolactin (P = 0.007). The mean size of RCCs did not show significant differences among the clinical indications for MRI (P ≥ 0.461). All RCCs showed abnormal signal on T2-weighted image and most (89%) showed neither fluid intensity nor intensity due to high protein content (i.e., isointense on T1-weighted imaging and hypointense on T2-weighted imaging compared with the normal anterior pituitary gland). Eighty-four patients with RCCs (74%) had follow-up MRI and the mean follow-up was 1.5 years. In follow-ups, five RCCs disappeared; the mean size of 10 RCCs increased and that of 6 RCCs decreased. These size changes were not statistically significant (P = 0.376). No signal intensity changes of RCCs were seen during the follow-up, except for 4 RCCs, whose protein content increased over time and T1 signals increased on imaging. Interobserver agreements were almost perfect for the MRI findings of RCCs (κ and ICC range, 0.81–1, P < 0.001). CONCLUSION RCCs were not uncommon in patients examined for endocrine-related diseases, and nearly 1 in 10 patients had an RCC. The size and signal intensities of RCCs may change over time and the evolution of RCCs is unpredictable. Most RCCs showed neither fluid intensity nor intensity due to high protein content on MRI, and all RCCs had an abnormal signal on T2-weighted imaging, thus eliminating the need to administer a contrast agent at follow-up imaging of the patients.

🔖

Cite This Article

GÜNEŞ, A., GÜNEŞ, S. Ö. (2020). The Neuroimaging Features of Rathke's Cleft Cysts in Children with Endocrine-related Diseases. Diagnostic and Interventional Radiology, Cilt: 26 - Sayı: 1, 61–67. https://ajindex.com/articles/152499

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Garrè ML, Cama A. Craniopharyngioma: modern concepts in pathogenesis and treatment. Curr Opin Pediatr 2007; 19:471–479. [CrossRef] Jagannathan J, Kanter AS, Sheehan JP, Jane Jr JA, Laws Jr ER. Benign brain tumors: sellar/parasellar tumors. Neurologic Clinics 2007; 25:1231–1249. [CrossRef] Lafferty AR, Chrousos GP. Pituitary tumors in children and adolescents. J Clin Endocrinol Metab 1999; 84:4317–4323. [CrossRef] Rennert J, Doerfler A. Imaging of sellar and parasellar lesions. Clin Neurol Neurosurg 2007; 109:111–124. [CrossRef] Delman BN. Imaging of pediatric pituitary abnormalities. Endocrinol Metab Clin North Am 2009; 38:673–698. [CrossRef] Lucas JW, Zada G. Imaging of the pituitary and parasellar region. Semin Neurol 2012; 32:320–331. [CrossRef] Voelker JL, Campbell RL, Muller J. Clinical, radiographic, and pathological features of symptomatic Rathke’s cleft cysts. J Neurosurg 1991; 74:535–544. [CrossRef] Takanashi J-I, Tada H, Barkovich AJ, Saeki N, Kohno Y. Pituitary cysts in childhood evaluated by MR imaging. AJNR Am J Neuroradiol 2005; 26:2144–2147.
  2. Teramoto A, Hirakawa K, Sanno N, Osamura Y. Incidental pituitary lesions in 1,000 unselected autopsy specimens. Radiology 1994; 193:161–164. [CrossRef] FitzPatrick M, Tartaglino LM, Hollander MD, Zimmerman RA, Flanders AE. Imaging of sellar and parasellar pathology. Radiol Clin North Am 1999; 37:101–121. [CrossRef] Cohan P, Foulad A, Esposito F, Martin NA, Kelly DF. Symptomatic Rathke’s cleft cysts: a report of 24 cases. J Endocrinol Invest 2004; 27:943–948. [CrossRef] El-Mahdy W, Powell M. Transsphenoidal management of 28 symptomatic Rathke’s cleft cysts, with special reference to visual and hormonal recovery. Neurosurgery 1998; 41:7–17. [CrossRef] Matsushima T, Fukui M, Fujii K, Kinoshita K, Yamakawa Y. Epithelial cells in symptomatic Rathke’s cleft cysts: a light- and electron-microscopic study. Surg Neurol 1988; 30:197–203. [CrossRef] Harrison MJ, Morgello S, Post KD. Epithelial cystic lesions of the sellar and parasellar region: a continuum of ectodermal derivatives? J Neurosurg 1994; 80:1018–1025. [CrossRef] Laws ER, Kanter AS. Rathke cleft cysts. J Neurosurg 2004; 101:571–572. [CrossRef] Mukherjee J, Islam N, Kaltsas G, et al. Clinical, radiological and pathological features of patients with Rathke’s cleft cysts: tumors that may recur. J Clin Endocrinol Metab 1997; 82:2357–2362. [CrossRef] Kim JE, Kim JH, Kim OL, et al. Surgical treatment of symptomatic Rathke cleft cysts: clinical features and re